-

KORU Medical Systems to Participate in Upcoming Industry Conferences

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced the Company will participate in upcoming industry conferences including the 2022 PDA Universe of Pre-Filled Syringes and Injection Devices Conference and the 12th Annual Partnership Opportunities in Drug Delivery (PODD®).

The 2022 PDA Universe of Pre-Filled Syringes and Injection Devices Conference focuses on the latest advances in the field. This conference will explore the future of pharmaceutical devices, such as rapid technological advances, that will push the industry ahead while bringing together industry experts to share their experiences, new developments, regulatory considerations, challenges, and industry trends in this exciting area. The conference will take place on October 18-19, 2022, in Palm Springs, California. Register for the event here.

The Company is scheduled to present at the 12th Annual Partnership Opportunities in Drug Delivery (PODD®) on Monday, October 24th, 2022, at 5:15 PM ET. PODD now in its 12th year, is committed to upholding its tradition of combining partnering, access to cutting-edge business and scientific content in the field of drug delivery, with loyal support from a top-notch speaking faculty. PODD provides access to a wide range of drug delivery technologies and partnering before, during, and after the event. The event will take place on October 24-25, 2022, at the Westin Copley Place, Boston. More information can be found here.

“The subcutaneous market is rapidly growing, and continuous advancements are made each year,” said Linda Tharby, President and CEO. “Industry conferences bring together leading experts in the field, and the Company is looking forward to attending these important industry conferences. More specifically, these two conferences can play vital roles in advancing KORU Medical’s strategy as we look to increase our penetration into the pre-filled syringe market and our overall novel therapies pipeline.”

About KORU Medical

KORU Medical develops, manufactures, and commercializes innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing and HIgH-Flo Subcutaneous Safety Needle Sets. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.

Contacts

Greg Chodaczek
347-620-7010
investor@korumedical.com

KORU Medical Systems, Inc.

NASDAQ:KRMD

Release Versions

Contacts

Greg Chodaczek
347-620-7010
investor@korumedical.com

More News From KORU Medical Systems, Inc.

KORU Medical Systems to Participate in the 8th Annual Lake Street Best Ideas Growth Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in investor meetings at the 8th Annual Lake Street Best Ideas Growth Conference in New York on Thursday, September 12, 2024. About KORU Medical Systems KORU Med...

KORU Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter With 22% Revenue Growth; Raises Full Year 2024 Guidance

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2024 and raised full year 2024 revenue and gross margin guidance. Financial Highlights Second quarter 2024 net revenues of $8.4 million, a 22%...

KORU Medical Systems to Participate in the Canaccord Genuity 44th Annual Growth Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024. KORU Medical's management is scheduled to present at the Canaccord Genuity 44th Annual Gro...
Back to Newsroom